ceftizoxime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 563 68401-81-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ceftizoxime sodium
  • ceftizoxime
  • ceftisomin
  • epocelin
A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.
  • Molecular weight: 383.40
  • Formula: C13H13N5O5S2
  • CLOGP: 0.06
  • LIPINSKI: 0
  • HAC: 10
  • HDO: 3
  • TPSA: 147.21
  • ALOGS: -3.22
  • ROTB: 5
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 93 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 260.82 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.72 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.50 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 81 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.521 Moderate 0.73
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.065 Moderate 0.73
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.589 10^-6 cm/s Moderate 0.73
dh-clint Dog hepatocyte intrinsic clearance 2.399 uL/min/10^6 cells Moderate 0.73
dppb Dog plasma protein binding (% unbound) 62.240 % Moderate 0.73
fcs-ppb Fetal calf serum protein binding (% unbound) 48.910 % Moderate 0.73
herg hERG pIC50 4.181 pIC50 Moderate 0.73
hh-clint Human hepatocyte intrinsic clearance 1.445 uL/min/10^6 cells Moderate 0.73
hlm-clint Human liver microsomal intrinsic clearance 3.631 uL/min/mg protein Moderate 0.73
hppb Human plasma protein binding (% unbound) 40.010 % Moderate 0.73
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,DYRK3,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,HIPK2,IKBKB,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PIM3,PRKAA1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2 74
kinase-selectivity-class ACVR2B,AXL,BRAF,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK7,MAPK8,PRKDC,STK33,SYK,TEK,TGFBR1,TTK,UHMK1 20
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 8.810 Moderate 0.73
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.541 Moderate 0.73
mh-clint Mouse hepatocyte intrinsic clearance 4.093 Moderate 0.73
mppb Mouse plasma protein binding (% unbound) 58.330 Moderate 0.73
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.317 Moderate 0.73
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 42.680 % Moderate 0.73
rat-kpuu-brain Rat brain Kpuu 0.011 % Moderate 0.73
rh-clint Rat hepatocyte intrinsic clearance 1.905 uL/min/10^6 cells Moderate 0.73
rh-fuinc Rat hepatocyte fraction unbound in incubation 92.040 % Moderate 0.73
rppb Rat plasma protein binding (% unbound) 38.360 % Moderate 0.73
solubility-dd Solubility at pH 7.4 in DMSO 957.194 uM Moderate 0.73

Approvals:

DateAgencyCompanyOrphan
Sept. 15, 1983 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DD07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:36047 antibacterial drug

Related Drugs by ATC class:

J01DD Third-generation cephalosporins 17 drugs
cefcapenecefdinircefditoren pivoxilcefetametcefiximecefmenoximecefodizimecefoperazonecefotaximecefpiramidecefpodoxime proxetilcefsulodin show all 17 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Streptococcal meningitis indication 4510004 DOID:11574
Meningitis indication 7180009 DOID:9471
Septicemia due to Escherichia coli indication 9323009
Bacterial septicemia indication 10001005 DOID:0040085
Gonorrhea indication 15628003 DOID:7551
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Staphylococcal pneumonia indication 22754005
Streptococcal septicemia indication 29577008
Acute gonococcal urethritis indication 29864006
Pneumonia due to Streptococcus indication 34020007
Gonorrhea of rectum indication 42746002
Lower respiratory tract infection indication 50417007
Pneumonia due to Escherichia coli indication 51530003
Klebsiella cystitis indication 60867007
Acute gonococcal endometritis indication 65295003 DOID:7527
Urinary tract infectious disease indication 68566005
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Bacterial infection due to Serratia indication 71120004
Rhinoscleroma indication 72409005 DOID:11336
Septicemia due to Bacteroides indication 79587009
Septicemia due to Serratia indication 82091000
Infection of bone indication 111253001
Infectious disease of abdomen indication 128070006
Infection due to Enterobacteriaceae indication 128945009
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Proteus pneumonia indication 195888009
Bacterial peritonitis indication 197171003
Pneumonia indication 233604007 DOID:552
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infectious disorder of joint indication 363162000
Infection due to Staphylococcus aureus indication 406602003
Osteomyelitis due to Staphylococcus aureus indication 428783003
Sepsis due to Staphylococcus aureus indication 448417001
Peptostreptococcus infection indication 135341000119101
Staphylococcus Peritonitis indication
Skin and Skin Structure Serratia Infection indication
E. Coli Peritonitis indication
Streptococcus Osteomyelitis indication
Proteus Mirabilis Osteomyelitis indication
Peptostreptococcus Peritonitis indication
Morganella Morganii Urinary Tract Infection indication
Staphylococcus Aureus Joint Infection indication
Skin and Skin Structure Peptococcus Infection indication
Peptostreptococcus Joint Infection indication
Staphylococcus Aureus Urinary Tract Infection indication
Peptococcus Osteomyelitis indication
Proteus Joint Infection indication
Streptococcal Pelvic Inflammatory Disease indication
Peptococcus Joint Infection indication
Peptostreptococcus Osteomyelitis indication
Bacteroides Joint Infection indication
Skin and Skin Structure Proteus Infection indication
Skin and Skin Structure Bacteroides Fragilis Infection indication
H. Influenzae Meningitis indication
Peptococcus Peritonitis indication
Staphylococcus Epidermidis Skin and Skin Structure Infection indication
Pelvic Inflammatory Disease with Neisseria Gonorrhea indication
Serratia Urinary Tract Infection indication
Klebsiella Pneumoniae Peritonitis indication
Bacteroides Osteomyelitis indication
E. Coli Pelvic Inflammatory Disease indication
Streptococcal Joint Infection indication
Pseudomonas Aeruginosa Urinary Tract Infection indication
Enterobacter Pneumonia indication
Streptococcal Peritonitis indication
Bacteroides Peritonitis indication
Providencia Urinary Tract Infection indication
Bacteroides Pneumonia indication
Pyrexia of unknown origin off-label use 7520000
Blood coagulation disorder contraindication 64779008 DOID:1247
Factor II deficiency contraindication 73975000
Kidney disease contraindication 90708001 DOID:557
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.58 acidic
pKa2 13.14 acidic
pKa3 3.25 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK
Beta-lactamase Enzyme WOMBAT-PK

External reference:

IDSource
4017998 VUID
N0000179458 NUI
D00923 KEGG_DRUG
68401-82-1 SECONDARY_CAS_RN
2192 RXNORM
C0007560 UMLSCUI
CHEBI:553473 CHEBI
CHEMBL528 ChEMBL_ID
CHEMBL1201019 ChEMBL_ID
DB01332 DRUGBANK_ID
D015296 MESH_DESCRIPTOR_UI
6533629 PUBCHEM_CID
10785 IUPHAR_LIGAND_ID
4743 INN_ID
C43C467DPE UNII
4386 MMSL
d00010 MMSL
002729 NDDF
004847 NDDF
372770006 SNOMEDCT_US
54577009 SNOMEDCT_US
5681006 SNOMEDCT_US
4017998 VANDF
4019666 VANDF

Pharmaceutical products:

None